|Bid||14.40 x 800|
|Ask||14.40 x 900|
|Day's Range||13.98 - 14.55|
|52 Week Range||1.97 - 17.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.08|
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...
On a per-share basis, the Pasadena, California-based company said it had a loss of 18 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR ) will be discussing their earnings results in their Q3 Earnings Call to be held on August 7, 2018 at 4:30 PM ...
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease.
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on August 7, 2018, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2018 third quarter ended June 30, 2018. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8452059. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8452059.
Drug stocks are dominating our list of top charts to watch. Arbutus Biopharma Corp. (ABUS) snapped back 55 cents to $11.35 on 417,300 shares traded Tuesday. Arrowhead Pharmaceuticals Inc. (ARWR) jumped 65 cents to $16.45 on 1 million shares traded Tuesday.
Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.
On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).
Arrowhead Pharmaceuticals Inc. today will present preclinical and initial clinical data on ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency, at the Alpha-1 National Education Conference in San Francisco.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi candidate, ARO-AAT, for the treatment of congenital alpha-1 antitrypsin deficiency. ARO-AAT was previously granted orphan drug designation by the United States Food and Drug Administration in February 2018. Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, said, “ARO-AAT has the potential to provide patients and physicians with a much-needed treatment option for liver disease associated with alpha-1 antitrypsin deficiency, a rare genetic disorder.
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMC ...
Arrowhead Pharmaceuticals Inc’s (NASDAQ:ARWR): Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s loss has recently broadened since it announced a -US$34.38MRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO ) Arrowhead Pharmaceuticals ...
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / Arrowhead Pharmaceuticals was seeing big gains in Monday's trading session after announcing that it has fully enrolled its phase 1 study of ARO-AAT, for alpha-1 ...
Arrowhead Pharmaceuticals Inc. today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).